DE3876125T2 - Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren. - Google Patents

Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.

Info

Publication number
DE3876125T2
DE3876125T2 DE8888301824T DE3876125T DE3876125T2 DE 3876125 T2 DE3876125 T2 DE 3876125T2 DE 8888301824 T DE8888301824 T DE 8888301824T DE 3876125 T DE3876125 T DE 3876125T DE 3876125 T2 DE3876125 T2 DE 3876125T2
Authority
DE
Germany
Prior art keywords
double
treatment
viral
strand rna
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888301824T
Other languages
English (en)
Other versions
DE3876125D1 (de
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM PHARMACEUTICALS CORP ROCKVILLE MD US
HEM Pharmaceuticals Corp
Original Assignee
HEM PHARMACEUTICALS CORP ROCKVILLE MD US
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM PHARMACEUTICALS CORP ROCKVILLE MD US, HEM Pharmaceuticals Corp filed Critical HEM PHARMACEUTICALS CORP ROCKVILLE MD US
Publication of DE3876125D1 publication Critical patent/DE3876125D1/de
Application granted granted Critical
Publication of DE3876125T2 publication Critical patent/DE3876125T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE8888301824T 1987-03-23 1988-03-02 Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren. Expired - Fee Related DE3876125T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2882387A 1987-03-23 1987-03-23
US07/125,097 US4950652A (en) 1987-03-23 1987-11-25 dsRNAs for combination therapy in the treatment of viral diseases

Publications (2)

Publication Number Publication Date
DE3876125D1 DE3876125D1 (de) 1993-01-07
DE3876125T2 true DE3876125T2 (de) 1993-06-09

Family

ID=26704119

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888301824T Expired - Fee Related DE3876125T2 (de) 1987-03-23 1988-03-02 Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.

Country Status (21)

Country Link
US (1) US4950652A (de)
EP (1) EP0286224B1 (de)
JP (1) JP2656938B2 (de)
KR (1) KR960013435B1 (de)
CN (1) CN1049357C (de)
AU (1) AU1256288A (de)
CA (1) CA1316832C (de)
DE (1) DE3876125T2 (de)
DK (1) DK156688A (de)
ES (1) ES2066782T3 (de)
FI (1) FI881305A (de)
GR (1) GR3006340T3 (de)
HU (1) HUT46542A (de)
IE (1) IE63823B1 (de)
IL (1) IL85646A (de)
NO (1) NO881246L (de)
NZ (1) NZ223868A (de)
OA (1) OA08724A (de)
PH (1) PH23333A (de)
PT (1) PT87039B (de)
RU (1) RU2016572C1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US9309574B1 (en) 1984-08-22 2016-04-12 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Molecular cloning of HIV-1 from immortalized cell lines
US5906980A (en) * 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
US5091374A (en) * 1987-07-17 1992-02-25 Hem Research Inc. Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
US5712257A (en) * 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
US4963532A (en) * 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
US4960592A (en) * 1989-04-17 1990-10-02 Lanocare Laboratories Lanolin and lanolin oil skin treatment composition
US5132292A (en) * 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
CA2102221A1 (en) * 1991-04-16 1992-10-17 William Carter Abrogation of viral resistance to nucleoside analogues by double-stranded rnas
EP0596912A4 (en) * 1991-07-16 1994-07-27 Hem Pharma Corp Modulation and diagnosis of cytokine dysfunctions.
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
WO1996040191A1 (en) 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
US5834443A (en) * 1996-05-21 1998-11-10 Masiello; Domenick J. Composition and method for treating herpes simplex
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
EP0998293A4 (de) * 1997-01-17 2002-07-17 Icn Pharmaceuticals Behandlungen von zytokin-bedingten krankheiten
LT4475B (lt) * 1997-02-28 1999-02-25 Virmantas Stunžėnas Informacinės ribonukleino rūgšties panaudojimas vaistinėse medžiagose, skirtose padidinti šios ribonukleino rūgšties koduojamo baltymo kiekį paciento ląstelėse
FR2766711B1 (fr) * 1997-08-04 2001-02-02 Sod Conseils Rech Applic Produit comprenant au moins un arn double brin en association avec au moins un devire du 6-benzyluracile pour une utilisation therapeutique simultanee, separee ou etalee dans le temps
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
SK287538B6 (sk) 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Syntetický gén obsahujúci dispergovanú alebo cudzorodú deoxyribonukleovú molekulu, génový konštrukt obsahujúci tento syntetický gén a prípravok obsahujúci tento syntetický gén
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US20080242627A1 (en) * 2000-08-02 2008-10-02 University Of Southern California Novel rna interference methods using dna-rna duplex constructs
DE10100588A1 (de) * 2001-01-09 2002-07-18 Ribopharma Ag Verfahren zur Hemmung der Expression eines Zielgens
EP1229134A3 (de) 2001-01-31 2004-01-28 Nucleonics, Inc Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
CN1617731A (zh) * 2001-12-14 2005-05-18 海米斯费克斯生物制药公司 双链rna在高效抗逆转录病毒治疗的策略性治疗干预中的应用
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
ATE508188T1 (de) 2002-02-01 2011-05-15 Life Technologies Corp Oligonukleotid-zusammensetzungen mit verbesserter wirksamkeit
EP3006043B1 (de) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatorische g,u-haltige oligoribonucleotide
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections
US20050137154A1 (en) * 2003-05-16 2005-06-23 Hemispherx Biopharma Treating server acute respiratory syndrome
WO2005007831A2 (en) * 2003-07-18 2005-01-27 Vanderbilt University Compositions of protein mimetics and methods of using same against hiv-1, sars-cov and the like
CN1867355A (zh) * 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
RU2272631C2 (ru) * 2004-04-20 2006-03-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Синергическая композиция для ингибирования вич
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
KR20080072934A (ko) * 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 면역자극성 올리고리보뉴클레오티드
US8075877B2 (en) 2006-03-08 2011-12-13 Hemispherx Biopharma Broad spectrum immune and antiviral gene modulation by oral interferon
CN101437534A (zh) * 2006-03-08 2009-05-20 半球生物制药公司 口服干扰素的广谱免疫和抗病毒基因调节作用
MX2010004734A (es) * 2007-10-29 2010-05-20 Cipla Ltd Nueva combinacion anti-retrovirica.
WO2009102496A2 (en) * 2008-02-15 2009-08-20 Hemispherx Biopharma, Inc. Selective agonist of toll-like receptor 3

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113162B1 (de) * 1982-09-16 1989-07-19 Hem Research, Inc. Wucherungshemmende Wirkung von ds-Ribonucleinsäuren auf Tumorzellen
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
AT390000B (de) * 1985-03-16 1990-02-26 Wellcome Found Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS

Also Published As

Publication number Publication date
AU1256288A (en) 1988-09-22
PT87039A (pt) 1988-04-01
CN88101606A (zh) 1988-12-28
NZ223868A (en) 1991-02-26
CA1316832C (en) 1993-04-27
CN1049357C (zh) 2000-02-16
PT87039B (pt) 1992-11-30
ES2066782T3 (es) 1995-03-16
US4950652A (en) 1990-08-21
NO881246L (no) 1988-09-26
KR880010777A (ko) 1988-10-24
RU2016572C1 (ru) 1994-07-30
HUT46542A (en) 1988-11-28
PH23333A (en) 1989-07-14
DK156688D0 (da) 1988-03-22
DK156688A (da) 1988-09-24
JPS6425A (en) 1989-01-05
IE880839L (en) 1988-09-23
IL85646A (en) 1993-05-13
DE3876125D1 (de) 1993-01-07
EP0286224B1 (de) 1992-11-25
KR960013435B1 (ko) 1996-10-05
IL85646A0 (en) 1988-08-31
FI881305A0 (fi) 1988-03-18
FI881305A (fi) 1988-09-24
EP0286224A2 (de) 1988-10-12
EP0286224A3 (en) 1988-12-07
NO881246D0 (no) 1988-03-21
JP2656938B2 (ja) 1997-09-24
IE63823B1 (en) 1995-06-14
GR3006340T3 (de) 1993-06-21
OA08724A (fr) 1989-03-31

Similar Documents

Publication Publication Date Title
DE3876125T2 (de) Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
DE3585981D1 (de) Behandlung gewebedegenerativer entzuendungskrankheiten.
OA08581A (en) Treatment of diseases caused by retroviruses.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3587741D1 (de) Behandlung von Hautkrankheiten.
DE3780091T2 (de) Behandlung von pilzinfektionen.
DE3670827D1 (de) Magnetische behandlung harten wassers.
DE3750934D1 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
PT88684A (pt) Metodo de tratamento fosfatidilico de doencas virais
DE3777861D1 (de) Behandlung von gasen.
DE3883966T2 (de) Behandlung durchlässiger membranen.
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
NO901396L (no) Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer.
NO881255L (no) Behandling av fluider.
DE3674321D1 (de) Behandlung geschmeidiger gewebe.
ATE82688T1 (de) Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
ATE135702T1 (de) Aryl- oder heteroaryl-1-alkyl-pyrrol-2- carbonsäure-derivate, zur behandlung von durch interleukin-1 hervorgerufenen erkrankungen
DE3777800D1 (de) Behandlung der wollstoffe.
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
DE3280419T2 (de) Medizinisches praeparat zur behandlung von hautleiden.
DE3668338D1 (de) Kontinuierliche behandlung von spannungslosem gewebe.
ATE121935T1 (de) D-asparaginsäure-beta-hydroxamat zur behandlung viraler infektionen und tumoren.
ATE77743T1 (de) Behandlung von pilzinfektionen.
ATE94086T1 (de) Behandlung durchlaessiger membranen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee